No evidence of molecular markers of piperaquine resistance in southeastern Nigeria.

ABSTRACT:

Background

Artemisinin‑based combination therapy (ACT) remains the first‑line treatment for uncomplicated malaria, yet its long‑term efficacy is threatened by Plasmodium falciparum resistance to both artemisinin derivatives and partner drugs. Routine surveillance of clinical efficacy and molecular‑resistance markers is therefore essential. Piperaquine (PPQ), the partner drug in dihydroartemisinin-piperaquine (DHA‑PPQ) is already compromised in Southeast Asia, and key PPQ‑resistance mutations have begun to surface in parts of Africa. No such data are available from Nigeria. Three PPQ‑resistanceassociated singlenucleotide polymorphisms (SNPs)-T93S, H97Y and F145Ilocated in exons 2 and 3 of the P. falciparum chloroquineresistance transporter gene (pfcrt), and copy‑number variation of

SUBMITTER: Ikegbunam M 

PROVIDER: S-EPMC12455774 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature